基于HPV16 E7蛋白CTLs抗原肽的病毒样颗粒治疗性疫苗的构建

doi:10.13523/j.cb.20150207

中国生物工程杂志

2015, Vol. 35

Issue (2): 45-51 DOI: 10.13523/j.cb.20150207

技术与方法

基于HPV16 E7蛋白CTLs抗原肽的病毒样颗粒治疗性疫苗的构建

褚晓杰^1,2,3, 李杨^1,2,3, 龙琼^1,2,3, 姚宇峰^1,2,3, 孙文佳^1,2,3, 黄惟巍^1,2,3, 杨旭^1,2,3, 刘存宝^1,2,3, 马雁冰^1,2,3

1. 中国医学科学院/北京协和医学院医学生物学研究所昆明 650118;
2. 云南省重大传染病疫苗研发重点实验室昆明 650118;
3. 云南省重大传染病疫苗工程技术研究中心昆明 650118

Development of a HPV16 E7 CTLs Peptides-based Virus-like Particle Therapeutic Vaccine

CHU Xiao-jie^1,2,3, LI Yang^1,2,3, LONG Qiong^1,2,3, YAO Yu-feng^1,2,3, SUN Wen-jia^1,2,3, HUANG Wei-wei^1,2,3, YANG Xu^1,2,3, Liu Cun-bao^1,2,3, MA Yan-bing^1,2,3

1. Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming 650118, China;
2. Yunnan Key Laboratory of Vaccine Research&Development on Severe Infectious Disease, Kunming 650118, China;
3. Yunnan Engineering Research Center of Vaccine Research and Development on Severe Infectious Disease, Kunming 650118, China

全文: PDF(970 KB) HTML

摘要：

目的: 构建呈递HPV16 E7 CTLs抗原表位的病毒样颗粒,并初步评价病毒样颗粒作为治疗性疫苗载体的潜能。方法: 根据文献选择有效的HPV16 E7 CTLs表位,合成其正负链寡核苷酸序列,并通过退火形成双链DNA片段。将片段克隆于表达乙肝核心抗原的重组质粒pThioHisA-HBcAg,使抗原肽得以呈现于病毒样颗粒。重组菌经IPTG诱导后经SDS-PAGE鉴定目的蛋白表达。菌体破碎后经硫酸铵盐析法和蔗糖密度梯度离心进行纯化,并经高效液相凝胶过滤色谱和电镜鉴定病毒样颗粒的存在。制备的病毒样颗粒免疫接种了TC-1细胞的肿瘤模型小鼠,检测小鼠肿瘤大小。此外,在体外以抗原肽刺激脾细胞,以ELISA检测IFN-γ表达水平。结果: 构建的三个重组表达质粒经酶切鉴定及测序分析证实构建正确。表达的重组蛋白大小与预期相符,并形成了病毒样颗粒。免疫小鼠后显示了抑制肿瘤增长的一定作用趋势。此外,抗原肽体外刺激促进了疫苗免疫小鼠脾细胞IFN-γ的表达,显示疫苗引起机体产生E7特异性的细胞免疫应答。结论: HBcAg VLPs是有潜能的治疗性疫苗载体。

关键词： 病毒样颗粒; 治疗性疫苗; 人乳头瘤病毒

Abstract:

Objective: To construct virus-like particles (VLPs) presenting CTLs epitopes of HPV16 E7, and assess its potentials to be an effective form of therapeutic vaccine. Methods: Three reported effective HPV16 E7 CTLs epitopes were selected and used to be presented by HBcAg VLPs. The oligonucleotides encoding for the three peptides were synthesized and inserted respectively into the plasmid pThioHisA-HBcAg. The recombinant plasmids were tansformed into DH5α cells, and the expression of the chimeric proteins were induced with IPTG and identified by SDS-PAGE. The proteins were purified with a procedure consists of ammonium sulfate precipitation and sucrose density gradient centrifugation, and the presence of VLPs was detected with HPLC of size-exclusion chromatography and electron microscopy. Mice received TC-1 graft were immunized with the mixed VLPs, and the dynamic changes of tumor size were recorded. In addition, the splenocytes isolated from the experimental mice were stimulated in vitro with the synthetic antigenic peptides and the expression of IFN-γ was measured by ELISA. Results: Three constructed recombinant plasmids were proven to be correct by restriction enzyme digestion and DNA sequencing. The recombinant proteins were expressed efficiently, and presented as VLPs. Tumor growth was suppressed in vaccinated mice. Furthermore, the IFN-γ expression of splenocytes was promoted by the stimulation of antigenic peptides, indicating that the VLPs caused the E7-specific cellular immune response. Conclusion: Presenting HPV E7 CTLs epitopes with HBcAg VLPs is a potential strategy for developing an effective therapeutic HPV vaccine.

Key words: Virus-like particles(VLPs) Therapeutic vaccine Human papillomavirus

收稿日期: 2014-11-26 出版日期: 2015-02-25

ZTFLH:

R392.11

基金资助:

国家自然科学基金(31270030)、云南省面上项目(2010ZC232)、中央高校基本科研业务费(2012N08)资助项目

通讯作者: 马雁冰 E-mail: may@imbcams.com.cn

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

引用本文:

褚晓杰, 李杨, 龙琼, 姚宇峰, 孙文佳, 黄惟巍, 杨旭, 刘存宝, 马雁冰. 基于HPV16 E7蛋白CTLs抗原肽的病毒样颗粒治疗性疫苗的构建[J]. 中国生物工程杂志, 2015, 35(2): 45-51.

CHU Xiao-jie, LI Yang, LONG Qiong, YAO Yu-feng, SUN Wen-jia, HUANG Wei-wei, YANG Xu, Liu Cun-bao, MA Yan-bing. Development of a HPV16 E7 CTLs Peptides-based Virus-like Particle Therapeutic Vaccine. China Biotechnology, 2015, 35(2): 45-51.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20150207 或 https://manu60.magtech.com.cn/biotech/CN/Y2015/V35/I2/45

[1] Parkin D M, Bray F, Ferlay J, et al.Global cancer statistics, 2002.CA Cancer J Clin,2005,55(2): 74-108.

[2] Bolhassani A, Mohit E, Rafati S.Different spectra of therapeutic vaccine development against HPV infections.Hum Vaccin,2009,5(10): 671-689.

[3] Niebler M, Qian X, Hofler D, et al.Post-translational control of IL-1beta via the human papillomavirus type 16 E6 oncoprotein: a novel mechanism of innate immune escape mediated by the E3-ubiquitin ligase E6-AP and p53.PLoS Pathog,2013,9(8): e1003536.

[4] Yu Y, Munger K.Human papillomavirus type 16 E7 oncoprotein inhibits the anaphase promoting complex/cyclosome activity by dysregulating EMI1 expression in mitosis.Virology,2013,446(1-2): 251-259.

[5] Jemon K, Young V, Wilson M, et al.An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy.PLoS One,2013,8(6): e66866.

[6] Monroy-Garcia A, Gomez-Lim M A, Weiss-Steider B, et al.Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.Arch Virol,2014,159(2): 291-305.

[7] Pokorna D, Polakova I, Kindlova M, et al.Vaccination with human papillomavirus type 16-derived peptides using a tattoo device.Vaccine,2009,27(27): 3519-3529.

[8] Ressing M E, van Driel W J, Brandt R M, et al.Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.J Immunother,2000,23(2): 255-266.

[9] Berzofsky J A, Ahlers J D, Janik J, et al.Progress on new vaccine strategies against chronic viral infections.J Clin Invest,2004,114(4): 450-462.

[10] Bolhassani A,Mohit E,Rafati S.Different spectra of therapeutic vaccine development against HPV infections.Hum Vaccin,2009,5(10):671-689.

[11] Schreurs M W, Kueter E W, Scholten K B, et al.A single amino acid substitution improves the in vivo immunogenicity of the HPV16 oncoprotein E7(11-20) cytotoxic T lymphocyte epitope.Vaccine,2005,23(31):4005-4010.

[12] Song Y C, Cheng H Y, Leng C H, et al.A novel emulsion-type adjuvant containing CpG oligodeoxynucleotides enhances CD8⁺ T-cell-mediated anti-tumor immunity.J Control Release,2014,173: 158-165.

[13] Klencke B, Matijevic M, Urban R G, et al.Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101.Clin Cancer Res,2002,8(5):1028-1037.

[1]	陈修月,周文锋,何庆,苏冰,邹亚文. 噬菌体Qβ病毒样颗粒的制备、纯化及鉴定[J]. 中国生物工程杂志, 2021, 41(7): 42-49.
[2]	谢航航,白红妹,叶超,陈永俊,袁明翠,马雁冰. 易发生聚集的重组HBcAg病毒样颗粒的纯化^*[J]. 中国生物工程杂志, 2020, 40(5): 40-47.
[3]	王国强,于茵茵,曾华辉,王旭东,吴玉彬,尚立芝,李玉林,张怡青,张西西,张振强,王云龙. 基于MS2噬菌体病毒样颗粒的RT-PCR检测新型冠状病毒(SARS-CoV-2)质控品制备^*[J]. 中国生物工程杂志, 2020, 40(12): 31-40.
[4]	王彦伟,李鹏昊,梁严予,关洋,逄文强,田克恭. 猪圆环病毒2型病毒样颗粒的高效组装技术研究^*[J]. 中国生物工程杂志, 2020, 40(11): 35-42.
[5]	白红妹,黄惟巍,刘存宝,孙文佳,杨旭,马雁冰. 共表达构建呈现人白细胞介素-13抗原肽的Qβ噬菌体病毒样颗粒 ^*[J]. 中国生物工程杂志, 2018, 38(5): 66-72.
[6]	孙文佳, 姚宇峰, 杨旭, 黄惟巍, 刘存宝, 龙琼, 褚晓杰, 马雁冰. 乙肝核心抗原病毒样颗粒呈现HPV 16L1抗原表位及特异抗体诱导[J]. 中国生物工程杂志, 2017, 37(3): 58-64.
[7]	杨旭, 黄惟巍, 姚宇峰, 刘存宝, 孙文佳, 白红妹, 马雁冰. 人乳头瘤病毒16型L1基因在毕赤酵母中表达的影响因素分析[J]. 中国生物工程杂志, 2017, 37(10): 1-7.
[8]	孙鹏艳, 黎奎, 刘存宝, 姚宇峰, 褚晓杰, 白红妹, 杨旭, 黄惟巍, 孙文佳, 马雁冰. 埃博拉病毒GP和VP40蛋白在哺乳动物细胞中的共表达及病毒样颗粒装配[J]. 中国生物工程杂志, 2016, 36(12): 66-71.
[9]	窦敏,张国广,于广福,张红心,沈明山,陈亮. 含口蹄疫病毒IRES RNA病毒样颗粒表达载体的构建[J]. 中国生物工程杂志, 2007, 27(9): 31-35.
[10]	宋敬东,王健伟,韩金祥,洪涛. 人乳头瘤病毒疫苗的研究进展[J]. 中国生物工程杂志, 2007, 27(4): 104-109.
[11]	刘丹如,宋长征,张更林,杜国利. 重组HIV-1壳体蛋白在转基因枸杞根系中的分泌表达[J]. 中国生物工程杂志, 2007, 27(2): 53-57.
[12]	王小兵,李茉,刘毅,田海梅,刘朝阳,李艳芬,曹冬艳,粱智,程冬婉,邵长君,张伟. HPV16+治疗性无佐剂蛋白疫苗—HPV16Z- Hsp65-E6/E7的构建、表达及纯化工艺研究[J]. 中国生物工程杂志, 2006, 26(12): 40-44.
[13]	孙红光,闫东梅,杜柏榕,朱迅. HBcAg和HBsAg前S1表位肽融合蛋白的表达研究[J]. 中国生物工程杂志, 2006, 26(03): 57-62.
[14]	孙晓光, 宋长征, 张更林. 转基因枸杞表达HIV-1壳体蛋白病毒样颗粒疫苗表达载体的构建[J]. 中国生物工程杂志, 2005, 25(8): 51-55.
[15]	高晶, 高雪涛, 段志强, 李文辉. 治疗性疫苗研究进展[J]. 中国生物工程杂志, 2003, 23(2): 83-85.

Viewed

Full text

Abstract

Cited

Shared

Discussed